EMA Authorised: Trajenta (linagliptin) — Boehringer Ingelheim International GmbH

View source ↗

Summary

Trajenta (linagliptin) has been authorised for use in the European Union for type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Trajenta (linagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Boehringer Ingelheim International GmbH. Decision date: 09/06/2026